AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study von Cortes, Jorge, Foran, James, Ghirdaladze, Darejan, DeVetten, Marcel P, Zodelava, Mamia, Holman, Peter, Levis, Mark J, Kantarjian, Hagop M, Borthakur, Gautam, James, Joyce, Zarringkar, Patrick P, Gunawardane, Ruwanthi N, Armstrong, Robert C, Padre, Norman M, Wierenga, Wendell, Corringham, Robert, Trikha, Mohit

Volltext

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor von Cortes, Jorge E., Ghirdaladze, Darejan, Foran, James M., DeVetten, Marcel P., Zodelava, Mamia, Levis, Mark J., Padre, Norman M., Joyce, James, Zarrinkar, Patrick P., Corringham, Robert

Volltext

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor von Cortes, Jorge, Foran, James M., Devetten, Marcel P., Giles, Francis J., James, Joyce, Zarrinkar, Patrick P., Silverman, Michael H., Kelly, Kerry A., Padre, Norman M., Bhagwat, Shripad, Wierenga, Wendell

Volltext

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicu... von WITZIG, Thomas E, GORDON, Leo I, GRILLO-LOPEZ, Antonio J, MULTANI, Pratik, WHITE, Christine A, CABANILLAS, Fernando, CZUCZMAN, Myron S, EMMANOUILIDES, Christos, JOYCE, Robin, POHLMAN, Brad L, BARTLETT, Nancy L, WISEMAN, Gregory A, PADRE, Norman

Volltext

A Convergent-Parallel Analysis on the Technical Assistance Provided by Information Technology Faculty Extensionists: Basis for Training and Extension Activities Plan von Olipas, Cris Norman, Luciano, Ruth G, Sison, Rosalie B, Padre, Jefrain M, Collado Jr., Marcelino C, Pula, Racquel L

Volltext